Due to the reported insufficient therapeutic efficacy of cblb−/− CD8+ T cell therapy alone in the B16 melanoma model using polyclonal T cells ([21] and data not shown), we combined ACT with a DC vaccine to induce an efficient in vivo selection of tumor antigen-specific T cells. The gene discussed is CD8A; the disease is neoplasm.